INTI · XBRL financial data

Inhibitor Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	0	—	—	—	—
Research and development	185	5	6	1,381	1,683	1,697
General and administrative	874	320	652	2,024	1,975	1,730
Total operating expenses	1,059	325	658	3,405	3,657	3,427
Operating income (loss)	(1,059)	(325)	(658)	(3,405)	(3,657)	(3,427)
Interest expense	—	15	23	—	—	—
Income tax expense (benefit)	0	0	55	—	—	—
Net income (loss)	(1,058)	(299)	12,106	(3,026)	(3,339)	(3,300)
Earnings per share, basic USD per share	—	0.00	0.03	(0.02)	(0.02)	(0.02)
Earnings per share, diluted USD per share	—	0.00	0.03	(0.02)	(0.02)	(0.02)
Weighted average shares, basic thousands of shares	—	376,248	366,184	171,950	172,263	172,512
Weighted average shares, diluted thousands of shares	—	376,248	367,777	171,950	172,263	172,512

Fiscal years (INTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	75	31	11,951	8,840	5,607	2,375
Prepaid and other current assets	—	—	24	109	88	72
Total current assets	107	59	11,975	8,949	5,695	2,447
Right-of-use asset	—	—	—	—	—	64
Total assets	132	59	11,975	8,949	5,695	2,511
Accounts payable	269	280	145	34	16	52
Accrued liabilities	—	53	123	631	694	690
Total current liabilities	425	680	679	665	710	766
Total liabilities	3,492	3,680	3,679	3,665	3,710	3,803
Accumulated deficit	(57,172)	(57,671)	(45,754)	(48,780)	(52,119)	(55,420)
Total stockholders' equity	(3,360)	(3,621)	8,296	5,284	1,985	(1,292)
Total liabilities and equity	132	59	11,975	8,949	5,695	2,511
Common shares outstanding (cover page) thousands of shares	375,876	376,858	171,793	172,024	172,324	172,574

Fiscal years (INTI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(1,058)	(299)	12,106	(3,026)	(3,339)	(3,300)
Stock-based compensation	229	38	—	14	40	23
Net cash from operating activities	(825)	(220)	11,741	(2,700)	(3,233)	(3,231)
Dividends paid	0	—	—	—	—	—
Net cash from financing activities	97	176	180	(411)	—	—
Net change in cash	(729)	(44)	11,921	(3,111)	(3,233)	(3,231)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
MetaVia	12,634	not reported	(3,762)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.